Today: 8 June 2026
Browse Category

NASDAQ:IBRX 18 January 2026 - 20 May 2026

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
20 May 2026
·
ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio shares rose 3.5% to $11.95 premarket Wednesday after reporting 2025 net product revenue of $113 million for Anktiva, up about 700% year over year. The company posted a 2025 net loss of $351.4 million and ended the year with $242.8 million in cash. Investors await a March FDA meeting on recombinant BCG. Director Barry J. Simon sold 175,000 shares last week under a prearranged plan.
25 February 2026
·
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio shares rose about 1% to $8.70 premarket after reporting ANKTIVA net product revenue of $113 million for 2025, up roughly 700% from 2024. The company posted a $351.4 million net loss and ended the year with $242.8 million in cash. ANKTIVA is now authorized in 33 countries, including recent European approval. Traders are watching cash burn and upcoming regulatory milestones.
23 February 2026
·
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio shares fell 12.1% to $6.45 Friday after reporting median overall survival has not been reached in its Phase 2 glioblastoma trial. BTIG raised its price target to $9 and kept a Buy rating. The company said the FDA requested more data for its ANKTIVA bladder cancer application but no new trials. Preliminary 2025 net product revenue was reported at $113 million, up about 700% year-over-year.
24 January 2026
·
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio shares fell 5.9% to $6.10 premarket after announcing an FDA meeting on possible resubmission of its ANKTIVA bladder-cancer drug. The FDA previously rejected the application for BCG-unresponsive papillary disease and has now requested more data. ImmunityBio plans to submit the information within 30 days. The company cites long-term trial data showing a 58.2% 12-month disease-free survival rate.
21 January 2026
·
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio shares soared 40% to $5.52 Friday after the company reported preliminary 2025 net product revenue of $113 million and new approvals for ANKTIVA in Saudi Arabia. Trading volume topped 182 million shares. Enrollment in its key bladder cancer trial is over 85% complete, with FDA submission targeted by late 2026. Early data from its CAR-NK cell therapy showed complete remission in two Waldenström lymphoma patients.
18 January 2026
··
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares surged 39.8% to $5.52 Friday after the company projected 2025 ANKTIVA net product revenue of $113 million, up about 700% from last year. The stock rose further to $6.04 in after-hours trading. Trial enrollment for its bladder cancer study reached over 85%, and new CAR-NK data showed a 15-month complete response in Waldenström lymphoma.
18 January 2026
·
1 2

Stock Market Today

  • Intesa Sanpaolo Sells 1000 MPS Shares at EUR 9.95 on Euronext Milan
    June 8, 2026, 3:20 PM EDT. Intesa Sanpaolo sold 1000 shares of Monte dei Paschi di Siena (MPS) on Euronext Milan for EUR 9.95 per share on June 8, 2026. The transaction reflects strategic asset adjustments by the Italian banking group amid market conditions. MPS shares trade on Euronext Milan, Italy's main stock exchange. This move could influence investor sentiment on both institutions.

Latest articles

Galaxy Digital spikes 24% as investors look at AI data center plans

Galaxy Digital spikes 24% as investors look at AI data center plans

8 June 2026
Galaxy Digital shares soared 23.6% to $31.07 after CEO Mike Novogratz said its West Texas AI data center—half of which is already leased—now represents more than half the company’s value, shifting focus from crypto to AI infrastructure; the stock’s surge outpaced bitcoin’s 2.7% rise as investors repriced Galaxy’s data-center business amid execution risks and strong analyst buy ratings.
Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

8 June 2026
Nu Holdings shares slid 3.1% to $11.60 as investors weighed CFO transition risks and rising credit costs, erasing last week’s 4.1% buyback-driven bounce; BofA downgraded the stock to Underperform with a $10 target, citing uncertainty from Lago’s exit, while Nu’s $1B buyback failed to stem a 10.7% weekly drop and 30.7% year-to-date decline, leaving shares just above their 52-week low.
Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

8 June 2026
Inno Holdings shares soared twentyfold to $20.97 after announcing a $3 million AI sales agent deal for its used mobile phone business, but investor risks remain with a recent $60 million at-the-market stock program and ongoing going-concern warnings in filings, as the project is still in early development and not yet commercially launched.
Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

8 June 2026
Emirates slashed June A380 flights on 10 major routes as soaring fuel costs and Middle East airspace disruption forced airlines to cut capacity, prompting IATA to halve its 2026 global profit forecast to $23 billion from $41 billion, with industry-wide seat reductions and rising fares expected as carriers struggle to absorb shocks during peak travel.
Wall Street Watches Microsoft’s $37 Billion AI Bet

Wall Street Watches Microsoft’s $37 Billion AI Bet

8 June 2026
Microsoft shares fell 1.5% to $410.30 as investors weighed bullish analyst calls and NHS England’s Copilot rollout against concerns that surging AI revenue—now at a $37 billion run rate—may not outpace rising costs and margin pressure from heavy infrastructure investment.
Go toTop